This is my prediction of the next uptrend towards Truforma's launch date. The first device from Zomedica.
ZOM is currently in an aggressive upward trend and is likely to continue in this trend. Why? Because you can see in the chart above that ZOM is currently in its next consolidation just like it was in January. During the making of this post the price has fallen below the resistance. This was also the case in January, but it was immediately corrected the next day (false outbreak).
Also the RSI also reveals the new uptrends.
Ultimately, I think the idea is that ZOM will go to $8 and stay there in the next consolidation until they make revenue for the first time.
I know that a stock price of $8 entails a huge market cap. But because of the hype of Truforma investors first condone that.
I would like to hear feedback from you guys and what you think will happen to the stock in the near future!
The annual report tells a somewhat different story. It seems they are not ready with their product launch. It might get delayed. That'll have a huge impact on the stock price. Plus the Execs have a plan where an arrangement has been made for 11M shares to be diluted. All mentioned in their SEC filings.
Johnny56231
⋅
@TrueNorth017, Hope not.... that will tank the stock to the 1S ...
UnknownUnicorn17184130
⋅
Next month is going to be fantastic. It’s almost time..
MillennialairesClub
⋅
Truforma public or. Commercializing March 30th
luigar007
⋅
Hello There!!
Can you explain to me what is the effect that this news can cause to ZOM trend?
"ANN ARBOR, Mich., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that the underwriter of its previously announced public offering of has exercised in full its over-allotment option to purchase an additional 13,697,368 common shares of Zomedica at a price to the public of $1.90 per share, less underwriting discounts and commissions. After giving effect to the full exercise of the over-allotment option, the gross proceeds are approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Zomedica.
H.C. Wainwright & Co. acted as the sole book-running manager for the offering."